Pharma & Healthcare

Independent equity research on Indian pharmaceutical, CDMO, diagnostics and hospital stocks. Each Zumedha report values the company with DCF, relative valuation, asset-based (NAV), earnings power (EPV) and sum-of-the-parts methods, then sets a clear Buy Range, Sell Range and risk-and-catalyst view. Coverage spans generics and formulations, API and specialty chemicals, contract research and manufacturing, biotech, and healthcare services. Pharma earnings hinge on USFDA compliance, US generic pricing, product pipelines, and India’s domestic formulation growth, and our reports track each of these.